The role of blood cell membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide

Biochemical and Biophysical Research Communications

Volumn 403, Issue 3-4, 2010, Pages 270-274

  Matos, Pedro M ^a   Freitas, Teresa ^a   Castanho, Miguel A R B ^a   Santos, Nuno C ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Dipole potential; Erythrocytes; HIV 1; Lymphocytes; Membrane; Sifuvirtide

Indexed keywords

4 [ 2 [ 6 (DIOCTYLAMINO) 2 NAPHTHALENYL]ETHENYL] 1 ( 3 SULFOPROPYL)PYRIDINIUM; FLUORESCENT DYE; LIPID; PEPTIDE; PHOSPHATIDYLCHOLINE; SIFUVIRTIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CELL; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DIPOLE; ERYTHROCYTE MEMBRANE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID BILAYER; LYMPHOCYTE MEMBRANE; MEMBRANE POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CELLS, CULTURED; ERYTHROCYTE MEMBRANE; HIV FUSION INHIBITORS; HIV-1; HUMANS; LYMPHOCYTES; MEMBRANE LIPIDS; PEPTIDES; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650172669     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.013     Document Type: Article

References (26)

1. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 2007, 6:1001-1018.
2. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 2004, 3:215-225.
3. He Y.X., Xiao Y.H., Song H.F., Liang Q., Ju D., Chen X., Lu H., Jing W.G., Jiang S.B., Zhang L.Q. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2008, 283:11126-11134.
4. Wang R.R., Yang L.M., Wang Y.H., Pang W., Tam S.C., Tien P., Zheng Y.T. Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem. Biophys. Res. Commun. 2009, 382:540-544.
5. Eron J.J., Gulick R.M., Bartlett J.A., Merigan T., Arduino R., Kilby J.M., Yangco B., Diers A., Drobnes C., DeMasi R., Greenberg M., Melby T., Raskino C., Rusnak P., Zhang Y., Spence R., Miralles G.D. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 2004, 189:1075-1083.
6. Greenberg M.L., Davison D., Jin J., Mosier S., Melby T., Sista P., Demasi R., Miralles D., Cammack N., Matthews T.J. In vitro antiviral activity of T-1249 a second generation fusion inhibitor. Antivir. Ther. 2002, 7(Suppl.1):S10.
7. Veiga A.S., Santos N.C., Loura L.M.S., Fedorov A., Castanho M.A.R.B. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J. Am. Chem. Soc. 2004, 126:14758-14763.
8. Veiga S., Henriques S., Santos N.C., Castanho M. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem. J. 2004, 377:107-110.
9. Matos P.M., Castanho M.A.R.B., Santos N.C. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS One 2010, 5:e9830.
10. Franquelim H.G., Loura L.M.S., Santos N.C., Castanho M.A.R.B. Sifuvirtide screens rigid membrane surfaces. Establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J. Am. Chem. Soc. 2008, 130:6215-6223.
11. Franquelim H.G., Veiga A.S., Weissmuller G., Santos N.C., Castanho M.A. Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor sifuvirtide towards phosphatidylcholine-rich rigid membranes. Biochim. Biophys. Acta 2010, 1798:1234-1243.
12. Gerber D., Pritsker M., Gunther-Ausborn S., Johnson B., Blumenthal R., Shai Y. Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a dl-amino acid-containing fusion peptide: possible recognition of the fusion complex. J. Biol. Chem. 2004, 279:48224-48230.
13. Quintana F.J., Gerber D., Kent S.C., Cohen I.R., Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J. Clin. Invest. 2005, 115:2149-2158.
14. Brugger B., Glass B., Haberkant P., Leibrecht I., Wieland F.T., Krasslich H.G. The HIV lipidome: a raft with an unusual composition. Proc. Natl. Acad. Sci. USA 2006, 103:2641-2646.
15. Asawakarn T., Cladera J., O'Shea P. Effects of the membrane dipole potential on the interaction of saquinavir with phospholipid membranes and plasma membrane receptors of Caco-2 cells. J. Biol. Chem. 2001, 276:38457-38463.
16. Cladera J., O'Shea P. Intramembrane molecular dipoles affect the membrane insertion and folding of a model amphiphilic peptide. Biophys. J. 1998, 74:2434-2442.
17. Gross E., Bedlack R.S., Loew L.M. Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential. Biophys. J. 1994, 67:208-216.
18. Matos P.M., Goncalves S., Santos N.C. Interaction of peptides with biomembranes assessed by potential-sensitive fluorescent probes. J. Pept. Sci. 2008, 14:407-415.
19. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 1986, 858:161-168.
20. Clarke R.J., Kane D.J. Optical detection of membrane dipole potential: avoidance of fluidity and dye-induced effects. Biochim. Biophys. Acta 1997, 1323:223-239.
21. Leidl K., Liebisch G., Richter D., Schmitz G. Mass spectrometric analysis of lipid species of human circulating blood cells. Biochim. Biophys. Acta 2008, 1781:655-664.
22. Castanho M.A., Fernandes M.X. Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur. Biophys. J. 2006, 35:92-103.
23. Hess C., Klimkait T., Schlapbach L., Del Zenero V., Sadallah S., Horakova E., Balestra G., Werder V., Schaefer C., Battegay M., Schifferli J.A. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002, 359:2230-2234.
24. Banki Z., Wilflingseder D., Ammann C.G., Pruenster M., Mullauer B., Hollander K., Meyer M., Sprinzl G.M., van Lunzen J., Stellbrink H.J., Dierich M.P., Stoiber H. Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J. Immunol. 2006, 177:3469-3476.
25. He W., Neil S., Kulkarni H., Wright E., Agan B.K., Marconi V.C., Dolan M.J., Weiss R.A., Ahuja S.K. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008, 4:52-62.
26. Beck Z., Brown B.K., Wieczorek L., Peachman K.K., Matyas G.R., Polonis V.R., Rao M., Alving C.R. Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS One 2009, 4:e8297.